Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320653 | 0.91 | PSIP1 (0.37) | PSIP1PSMB5PSMB1GRM2 | |
| SCHEMBL244658 | 0.91 | PSIP1 (0.43) | PSIP1CYP3A4PSMB5PSMB1 | |
| SCHEMBL245525 | 0.91 | PSIP1 (0.43) | PSIP1CYP3A4PSMB5PSMB1 | |
| SCHEMBL246571 | 0.90 | PSIP1 (0.43) | PSIP1CYP3A4PSMB5PSMB1 | |
| SCHEMBL15182746 | 0.85 | PSIP1 (0.37) | PSIP1PSMB5PSMB1GRM2 | |
| SCHEMBL3299227 | 0.82 | PSIP1 (0.35) | PSIP1PSMB5 | |
| SCHEMBL3320486 | 0.82 | PSIP1 (0.35) | PSIP1PSMB5 | |
| SCHEMBL15182616 | 0.82 | PSIP1 (0.35) | PSIP1PSMB5PSMB1 | |
| SCHEMBL1699366 | 0.80 | PSIP1 (0.43) | PSIP1CYP3A4GRM2NR1I2 | |
| SCHEMBL1699326 | 0.80 | PSIP1 (0.43) | PSIP1CYP3A4GRM2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | PSIP1 3417/4885CYP3A4 1995/4885PSMB5 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.